FDA To Create List Of Drug Development Obstacles
This article was originally published in The Pink Sheet Daily
Executive Summary
Roadblocks on the "critical path to new products" will be identified for safety assessment, evaluation of medical utility and product industrialization. FDA’s Science Board will meet in April to discuss the issue.